Technical Specifications of Pediatric Ambulatory Care Sensitive Condition Hospitalizations

Size: px
Start display at page:

Download "Technical Specifications of Pediatric Ambulatory Care Sensitive Condition Hospitalizations"

Transcription

1 Technical Specificatins f Pediatric Ambulatry Care Sensitive Cnditin Hspitalizatins Surce: The Canadian Institute fr Health Infrmatin Database(s): Discharge Abstract Database (DAD) Level(s) f Care (facility type): Acute Care (excluding Quebec) Fiscal Year(s): 2014/15 and 2015/16 (cmbined) Scpe: All acute paediatric inpatient recrds, including deaths submitted t the DAD fr fiscal years 2014/15 and 2015/16. Grupings: Neighburhd Incme Quintile f patient pstal cde Cases frm the Yukn, Nrthwest Territries and Nunavut will be gruped, due t the lw number f facilities in these prvinces / territries. 1. ASTHMA Numeratr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 2-17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde f Asthma (J45.-) Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn AND Patients with any f the fllwing diagnsis cdes (in any diagnsis cde lcatin) n the abstract: E84.^ - Cystic fibrsis J Other disrders f the lung P27.^ - Chrnic respiratry disease rig. in the perinatal perid P28.^ - Other respiratry disease rig. in the perinatal perid Q30-Q34 - Cngenital malfrmatins f the respiratry system Q Other cngenital malfrmatin f arta Q Cngenital stensis and stricture f esphagus

2 2 Q Oesphageal web Q Situs inversus Denminatr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 2-17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde = any diagnsis cde Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn Include all acute hspitalizatins where the MRDx is the indicatr f interest, including multiple ccurrences within the tw (2) year study perid. Include all recrds fr the receiving Acute Care facilities where the patient was transferred frm an Emergency Department t the receiving Acute Care facility and the MRDx is the indicatr f interest. Exclude all recrds fr the receiving Acute Care facilities where the patient was transferred frm ne (1) Acute Care facility t the receiving Acute Care facility and the MRDx is the indicatr f interest. 2. DIABETES SHORT TERM COMPLICATIONS Numeratr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 6-17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde f Diabetes: E Type 1 diabetes mellitus with cma E Type 2 diabetes mellitus with cma E Other specified diabetes mellitus with cma E Unspecified diabetes mellitus with cma E Type 1 diabetes mellitus with ketacidsis E Type 2 diabetes mellitus with ketacidsis E Other specified diabetes mellitus with ketacidsis E Unspecified diabetes mellitus with ketacidsis E Type 1 diabetes mellitus with lactic acidsis E Type 2 diabetes mellitus with lactic acidsis

3 3 E Other specified diabetes mellitus with lactic acidsis E Unspecified diabetes mellitus with lactic acidsis E Type 1 diabetes mellitus with ketacidsis with lactic acidsis E Type 2 diabetes mellitus with ketacidsis with lactic acidsis E Other specified diabetes mellitus with ketacidsis with lactic acidsis E Unspecified diabetes mellitus with ketacidsis with lactic acidsis E Type 1 diabetes mellitus with pr cntrl, s described E Type 2 diabetes mellitus with pr cntrl, s described E Other specified diabetes mellitus with pr cntrl, s described E Unspecified diabetes mellitus with pr cntrl, s described Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn Denminatr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 6-17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde = any diagnsis cde Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn Include all acute hspitalizatins where the MRDx is the indicatr f interest, including multiple ccurrences within the tw (2) year study perid. Include all recrds fr the receiving Acute Care facilities where the patient was transferred frm an Emergency Department t the receiving Acute Care facility and the MRDx is the indicatr f interest. Exclude all recrds fr the receiving Acute Care facilities where the patient was transferred frm ne (1) Acute Care facility t the receiving Acute Care facility and the MRDx is the indicatr f interest.

4 4 3. PERFORATED APPENDIX ADMISSIONS Numeratr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 1-17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde f Acute Appendicitis with Peritnitis: K Acute appendicitis with generalized peritnitis K Acute appendicitis with lcalized peritnitis Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn Denminatr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 1-17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde f Appendicitis: K Acute appendicitis with generalized peritnitis K35.3 Acute appendicitis with lcalized peritnitis K35.8 Acute appendicitis, ther and unspecified K36 - Other appendicitis K37 - Unspecified appendicitis Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn If a patient has multiple hspital admissins with an MRDx f appendicitis r is transferred t anther acute facility with an MRDx f appendicitis, nly include the first ccurrence, fr that patient, fr that specific indicatr in the numeratr/denminatr. The patient will nly be cunted nce fr this indicatr.

5 5 4. DEHYDRATION AND GASTROENTERITIS (COMBINED) Numeratr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 3 mnths -17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde f Gastrenteritis: A08.^ - Viral and ther specified intestinal infectins A09.^ - Other gastrenteritis and clitis f infectius and unspecified rigin K Nninfective gastrenteritis and clitis, unspecified K Other specified nninfective gastrenteritis and clitis OR Cmbinatin cding f a Mst Respnsible Diagnsis (MRDx) cde f Dehydratin: E86.^ - Vlume depletin P Dehydratin f newbrn AND Gastrenteritis cde with a diagnsis type f 1, 2, W, X, r Y: A08.^ - Viral and ther specified intestinal infectins A09.^ - Other gastrenteritis and clitis f infectius and unspecified rigin K Nninfective gastrenteritis and clitis, unspecified K Other specified nninfective gastrenteritis and clitis Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn AND Patients with any f the fllwing diagnsis cdes (in any diagnsis cde lcatin) n the abstract: Bacterial r ther gastrenteritis A02.^ - Other salmnella infectins A03.^ - Shigellsis A04.^ - Other bacterial intestinal infectins A05.^ - Other bacterial fdbrne intxicatins, nt elsewhere classified A06.^ - Amebiasis A07.^ - Other prtzal intestinal diseases B Candidal enteritis Gastrintestinal abnrmalities K50.^ - Crhn's disease [reginal enteritis] K51.^ - Ulcerative clitis K Gastrenteritis and clitis due t radiatin K Txic gastrenteritis and clitis K Allergic and dietetic gastrenteritis and clitis K Indeterminate clitis

6 6 K90.^ - Intestinal malabsrptin K Pstsurgical malabsrptin, nt elsewhere classified K Mucsitis (ulcerative) f the digestive system Denminatr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 3 mnths - 17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde = any diagnsis cde Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn Include all acute hspitalizatins where the MRDx is the indicatr f interest, including multiple ccurrences within the tw (2) year study perid. Include all recrds fr the receiving Acute Care facilities where the patient was transferred frm an Emergency Department t the receiving Acute Care facility and the MRDx is the indicatr f interest. Exclude all recrds fr the receiving Acute Care facilities where the patient was transferred frm ne (1) Acute Care facility t the receiving Acute Care facility and the MRDx is the indicatr f interest. 5. URINARY TRACT INFECTION Numeratr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 3 mnths -17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde f Urinary Tract Infectin: N10 - Acute tubule-interstitial nephritis N Renal and perinephric abscess N Acute cystitis N Urinary tract infectin, site nt specified N Renal tubule-interstitial disease, unspecified N12 -Tubul-interstitial nephritis, nt specified as acute r chrnic N Pyelitis cystica N Pyelureteritis cystica

7 7 N Ureteritis cystica Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn AND Patients with any f the fllwing diagnsis cdes (in any diagnsis cde lcatin) n the abstract: Immuncmprmised B24 - Human immundeficiency virus [HIV] disease B59 - Pneumcystsis (J17.3*) C81-C96 - Malignant neplasms f lymphid, haematpietic and related tissue D47.^ - Other neplasms f uncertain r unknwn behaviur f lymphid, haematpietic and related tissue D57.^ - Sickle-cell disrders D61.^ - Other aplastic anaemias D80.^ - Immundeficiency with predminantly antibdy defects D81.^ - Cmbined immundeficiencies D82.^ - Immundeficiency assciated with ther majr defects D83.^ - Cmmn variable immundeficiency D84.^ - Other immundeficiencies D89.^ - Other disrders invlving the immune mechanism, nt elsewhere classified T86.^ - Failure and rejectin f transplanted rgans and tissues Z94.^ - Transplanted rgan and tissue status B18.^ - Chrnic viral hepatitis D Hypsplenism D Hypersplenism Q Cngenital malfrmatins f spleen D Chrnic cngestive splenmegaly D Abscess f spleen Kidney/urinary tract abnrmalities N11.^ - Chrnic tubul-interstitial nephritis N13.^ - Obstructive and reflux urpathy N14.^ - Drug- and heavy-metal-induced tubul-interstitial and tubular cnditins N Balkan nephrpathy N Other specified renal tubule-interstitial diseases N16.^ - Renal tubul-interstitial disrders in diseases classified elsewhere N17.^ - Acute renal failure N18.^ - Chrnic kidney disease N19 - Unspecified kidney failure N20-N23 - Urlithiasis N25-N29 - Other disrders f kidney and ureter N Interstitial cystitis (chrnic) N Other chrnic cystitis N Trignitis N Irradiatin cystitis N Other cystitis- includes abscess f bladder/cystitis cystic glandularis

8 8 N Cystitis, unspecified N31.^ - Neurmuscular dysfunctin f bladder, nt elsewhere classified N Bladder-neck bstructin N Tuberculsis cystitis N Bladder disrders in ther diseases classified elsewhere N34.^ - Urethritis and urethral syndrme N35.^ - Urethral stricture N36.^ - Other disrders f urethra N37.^ - Urethral disrders in diseases classified elsewhere N Persistent prteinuria, unspecified N Other specified disrders f urinary system N06.^ - Islated prteinuria with specified mrphlgical lesin Q60-Q64 - Cngenital malfrmatins f the urinary system E1*.23 + N08.3^ - Diabetes Mellitus with ESRD Denminatr: Inclusins: Analytical Institutin Type = Acute Inpatient AND Submitting Prvince/Territry = All (excluding Quebec) AND Patients age 3 mnths - 17 (inclusive, including deaths) years ld nly AND Canadian residents nly (include hmeless and unknwn) AND Mst Respnsible Diagnsis (MRDx) cde = any diagnsis cde Exclusins: Newbrns, Stillbirths, and Cadaveric Dnatins AND Obstetrical recrds with the fllwing diagnsis cdes in any psitin: O00 O99 (inclusive) - Pregnancy, Childbirth and the Puerperium Z37.^ - Outcme f Delivery A34 - Obstetrical Tetanus P Terminatin f pregnancy, affecting fetus and newbrn Include all acute hspitalizatins where the MRDx is the indicatr f interest, including multiple ccurrences within the tw (2) year study perid. Include all recrds fr the receiving Acute Care facilities where the patient was transferred frm an Emergency Department t the receiving Acute Care facility and the MRDx is the indicatr f interest. Exclude all recrds fr the receiving Acute Care facilities where the patient was transferred frm ne (1) Acute Care facility t the receiving Acute Care facility and the MRDx is the indicatr f interest.

ICD-10-CM Coding Basics Chapter Specifics

ICD-10-CM Coding Basics Chapter Specifics ICD-10-CM Cding Basics Chapter Specifics Chapter 15 Pregnancy, Childbirth and the Puerperium Vilma Smith, LVN, CPC, CCS Debra Bales, LVN, CPC Jnay Rischer, CPC 1 Rev. May 2015 ICD-10-CM Cnventins General

More information

APPENDIX A Certification of Advanced Disease:

APPENDIX A Certification of Advanced Disease: APPENDIX A Certificatin f Advanced Disease: Name: DOB: Member ID: Name f Palliative Care Prgram: A. General Criteria: Check each f the fllwing that apply (All needed fr eligibility). Patient wh is likely

More information

Solid Organ Transplant Benefits to Change for Texas Medicaid

Solid Organ Transplant Benefits to Change for Texas Medicaid Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a

More information

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin

More information

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure

More information

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038) Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December

More information

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038) Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December

More information

Paediatric Sepsis Form. Sinéad Horgan SSWHG Sepsis Lead

Paediatric Sepsis Form. Sinéad Horgan SSWHG Sepsis Lead Paediatric Sepsis Frm Sinéad Hrgan SSWHG Sepsis Lead www.hse.ie/sepsis Definitin A life-threatening rgan dysfunctin due t a dysregulated hst respnse t infectin N cnfirmatry test Bld cultures are psitive

More information

Cognitive enhancers for the treatment of Alzheimer s disease

Cognitive enhancers for the treatment of Alzheimer s disease Cmprehensive Research Plan: Cgnitive enhancers fr the treatment f Alzheimer s disease Pharmacepidemilgy Unit February 13 th, 2015 30 Bnd Street, Trnt ON, M5B 1W8 www.dprn.ca inf@dprn.ca 2 ODPRN Drug Class

More information

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070) Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD

More information

Child s Name: Date of Birth: TAKE THIS SHEET TO EVERY DOCTOR S APPOINTMENT

Child s Name: Date of Birth: TAKE THIS SHEET TO EVERY DOCTOR S APPOINTMENT Date f Birth: TAKE THIS SHEET TO EVERY DOCTOR S APPOINTMENT Prtable Medical Summary Name: Date Updated: / / Address: Phne: Mbile: E-mail: DOB: SSN: - - Allergies: Pertinent Persnal Characteristics: What

More information

Measure Information Form

Measure Information Form Release Ntes: Measure Infrmatin Frm Versin 2.0 **NQF-ENDORSED VOLUNTRY CONSENSUS STNDRDS FOR HOSPITL CRE** Measure Set: Heart Failure (HF) Set Measure ID#: Measure Infrmatin Frm Perfrmance Measure Name:

More information

ICD-10-CM Coding Basics Chapter Specifics

ICD-10-CM Coding Basics Chapter Specifics ICD-10-CM Cding Basics Chapter Specifics Chapter 10 Diseases f the Respiratry System Vilma Smith, LVN, CPC, CCS AHIMA Apprved ICD-10-CM/PCS Trainer Debra Bales, LVN, CPC 1 Rev. May 2015 ICD-10-CM Cnventins

More information

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights. HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,

More information

Nonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer

Nonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer Nnclinical factrs assciated with premature terminatin f adjuvant chemtherapy fr stage I-III breast cancer Xia-Cheng Wu, Trevr Thmpsn, Meichin Hsieh, Meijia Zhu, Patricia Andrews, Michelle Lch, Timthy Styles,

More information

ACRIN 6666 Screening Breast US Follow-up Assessment Form

ACRIN 6666 Screening Breast US Follow-up Assessment Form Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related

More information

Influenza (Flu) Fact Sheet

Influenza (Flu) Fact Sheet Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder

More information

LTCH QUALITY REPORTING PROGRAM

LTCH QUALITY REPORTING PROGRAM 4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04

More information

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

Request for Prior Authorization for Click here to enter text. Website Form   Submit request via: Fax Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...

More information

Extrapulmonary Respiratory Problems. During the First Week of Life

Extrapulmonary Respiratory Problems. During the First Week of Life Extrapulmnary Respiratry Prblems During the First Week f Life Jn Palmer, VMD, DACVIM Chief, Nenatal Intensive Care Service New Bltn Center, University f Pennsylvania, USA Nenatal Respiratry Prblems Upper

More information

BANKMED MEDICAL SCHEME. MEDICINE ADVISORY SERVICES (Chronic Medicine Benefit) GENERAL INFORMATION

BANKMED MEDICAL SCHEME. MEDICINE ADVISORY SERVICES (Chronic Medicine Benefit) GENERAL INFORMATION BANKMED MEDICAL SCHEME MEDICINE ADVISORY SERVICES (Chrnic Medicine Benefit) GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Cnditins cvered under Bankmed s chrnic medicatin benefit are detailed belw. REGISTRATION

More information

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management

More information

Επείγοντα καρδιολογικά προβλήματα- Διαγνωστικές και θεραπευτικές προκλήσεις Οξεία περικαρδίτιδα

Επείγοντα καρδιολογικά προβλήματα- Διαγνωστικές και θεραπευτικές προκλήσεις Οξεία περικαρδίτιδα Επείγοντα καρδιολογικά προβλήματα- Διαγνωστικές και θεραπευτικές προκλήσεις Οξεία περικαρδίτιδα Γ. Λάζαρος Επιμελητής Α Α Πανεπιστημιακή Καρδιολογική Κλινική Ιπποκράτειο Γ.Ν.Α The nrmal pericardium is

More information

Ontario s Referral and Listing Criteria for Adult Lung Transplantation

Ontario s Referral and Listing Criteria for Adult Lung Transplantation Ontari s Referral and Listing Criteria fr Adult Lung Transplantatin Versin 2.0 Trillium Gift f Life Netwrk Adult Lung Transplantatin Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient referral

More information

High Performance Network Quality Criteria for Designation

High Performance Network Quality Criteria for Designation Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain

More information

Michigan Primary Care Transformation Project Performance Incentive Technical Manual

Michigan Primary Care Transformation Project Performance Incentive Technical Manual Michigan Primary Care Transfrmatin Prject 2016 Perfrmance Incentive Technical Manual Fr Physician Organizatins, Physician Hspital Organizatins, Independent Practice Assciatins and Primary Care Practices

More information

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service)

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service) 2013 DATA COLLECTION GUIDE Summary Data Submissin Optimal Asthma Care (07/01/2012 t 06/30/2013 Dates f Service) Htline: 612-746-4522 E-mail: supprt@mncm.rg Data Prtal: https://data.mncm.rg/lgin MN Cmmunity

More information

Kentucky Medically Frail Medical Condition Guide v5 for Providers Supplement to the Kentucky Medically Frail Provider Attestation Form

Kentucky Medically Frail Medical Condition Guide v5 for Providers Supplement to the Kentucky Medically Frail Provider Attestation Form Page 1 f 9 Kentucky Medically Frail Medical Cnditin Guide v5 fr Prviders Supplement t the Kentucky Medically Frail Prvider Attestatin Frm This Guide is a reference t Medicaid Prviders and Clinicians as

More information

Measure Specific Guidelines for Comprehensive Diabetes Care (CDC)

Measure Specific Guidelines for Comprehensive Diabetes Care (CDC) Measure Specific Guidelines fr Cmprehensive Diabetes Care (CDC) Descriptin: Members age 18-75 years f age with diabetes (Type 1 and Type 2)* that had all f the fllwing: *Members in hspice are excluded

More information

o Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient

o Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient Image Surce: https://s-media-cache-ak0.pinimg.cm/736x/7c/29/91/7c2991805f004e1ca05e42a79883f4a7.jpg 6/30/2017 Curse Objectives A Practical Guide t Cding fr Audilgists in 2017 Megan Keirans, AuD University

More information

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP

Continuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit

More information

Medical Student Immunization Requirements

Medical Student Immunization Requirements Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

This information shows what new challenges are likely to require prevention efforts moving forward.

This information shows what new challenges are likely to require prevention efforts moving forward. Release f CDC s Healthcare-Assciated Infectins (HAI) Pint Prevalence Survey and Annual Natinal and State HAI Prgress Reprt Embarged until: Wednesday, March 26 th at 12 nn ET Key Messages Overall These

More information

ITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.

ITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child. Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet

More information

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP MEDICATION GUIDE Piglitazne (pie-h-glit-ah-zhn) and Metfrmin (met-fore-min) Hydrchlride Tablets USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride tablets

More information

Episodes of Care Risk Adjustment

Episodes of Care Risk Adjustment Episodes of Care Risk Adjustment Episode Types Wave 1 Asthma Acute Exacerbation Perinatal Total Joint Replacement Wave 2 Acute Percutaneous Coronary Intervention COPD Acute Exacerbation Non-acute Percutaneous

More information

Diabetes: HbA1c Poor Control (NQF 0059)

Diabetes: HbA1c Poor Control (NQF 0059) Diabetes: HbA1c Pr Cntrl (NQF 0059) EMeasure Name Diabetes: HbA1c Pr Cntrl EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement January 1, 20xx thrugh Perid December

More information

Oral Surgery (Facial Pain) Service Specification

Oral Surgery (Facial Pain) Service Specification Oral Surgery (Facial Pain) Service Specificatin Service Cmmissiner Lead Prvider Lead Perid 2. Oral Surgery Facial Pain (SBCH Ref N. SS_046) 1. Purpse 1.1 Aims T prvide a Cnsultant-led specialist diagnstic,

More information

Isle of Wight Joint Strategic Needs Assessment: Core Dataset 2009

Isle of Wight Joint Strategic Needs Assessment: Core Dataset 2009 Isle of Wight Joint Strategic Needs Assessment: Core Dataset 2009 Domain: Burden of Ill Health Indicator: Hospital Admissions - Top 10 Causes Sub-Domain: Misc Indicator References: JSNA Core Dataset number

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...

More information

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009 CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...

More information

NPCR CLINICAL EDIT CHECKS

NPCR CLINICAL EDIT CHECKS NPCR CLINICAL EDIT CHECKS FCDS Annual Meeting July 26, 2013 Sunrise, Flrida Steven Peace, CTR FCDS Data Quality Staff PURPOSE OF CLINICAL EDIT CHECKS The primary purpse f the Clinical Check edits is t

More information

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP MEDICATION GUIDE Piglitazne and Metfrmin Hydrchlride (PYE GLI ta zne and met FOR min HYE-dre- KLOR-ide)Tablets, USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride

More information

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.

More information

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will: Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin

More information

Risk factors in health and disease

Risk factors in health and disease Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

Υποτροπιάζουσες Περικαρδίτιδες: Τι νεότερο; Γεώργιος Λάζαρος Επιμελητής Α Α Πανεπιστημιακή Καρδιολογική Κλινική Ιπποκράτειο Γ.Ν.

Υποτροπιάζουσες Περικαρδίτιδες: Τι νεότερο; Γεώργιος Λάζαρος Επιμελητής Α Α Πανεπιστημιακή Καρδιολογική Κλινική Ιπποκράτειο Γ.Ν. Υποτροπιάζουσες Περικαρδίτιδες: Τι νεότερο; Γεώργιος Λάζαρος Επιμελητής Α Α Πανεπιστημιακή Καρδιολογική Κλινική Ιπποκράτειο Γ.Ν. Αθηνών Recurrent pericarditis after an initial episde f pericarditis ranges

More information

2018 CMS Web Interface

2018 CMS Web Interface CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4

More information

Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline

Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline Practice Guideline: Clinical Guide Cnsensus Recmmendatins fr the Management f Chrnic Lymphcytic Leukemia: Primary Care Guideline CCMB Practice Guideline Clinical Guide Develped by: Lymphprliferative Disrders

More information

Significance of Chronic Kidney Disease in 2015

Significance of Chronic Kidney Disease in 2015 1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care

More information

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic

More information

CARDIOLOGY Referral Guidance Sheet

CARDIOLOGY Referral Guidance Sheet Tyren, 3 heart transplant CARDIOLOGY I wish t be a fireman DEAR CARDIOLOGY HEALTH CARE PROFESSIONAL, USUALLY QUALIFYING CARDIOLOGY CONDITIONS: Cmplex cngenital heart disease, such as: Single ventricle

More information

Important Information

Important Information Grup Health Pharmacy Administratin GSE-B2N-02 2921 Naches Ave SW PO Bx 9009 Rentn, WA 98057-9009 Grup Health Cperative Grup Health Optins, Inc. ghc.rg Imprtant Infrmatin February 6, 2017 Dear Prvider,

More information

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.6 Cmpleted: Nvember 28, 2018 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins

More information

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control NQF 0075 Ischemic Vascular Disease (IVD): Cmplete Lipid Panel and LDL Cntrl Initial Patient Ppulatin: Numeratr(1): Numeratr(2): N Exclusin: Denminatr: D Exceptin: D Exclusin: Patients 18 years f age and

More information

Medicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes

Medicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes Medicare Advantage 2019 Advance Ntice Part 1 21 st Century Cures Act Methdlgical Changes Review f Relevant Prvisins with Expert Insight January 2018 PULSE8 is privileged t bring yu a summary f key Medicare

More information

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

Ontario 2018 provincial election issues backgrounder

Ontario 2018 provincial election issues backgrounder Ontari 2018 prvincial electin issues backgrunder Dietitians f Canada Pririties May 2018 Access t dietitians in Ontari s health system Diet is the #1 risk factr fr chrnic diseases that cst Ontari $90 billin

More information

This table cannot be relied upon in the absence of: PA Medical Directive #8 - Gastroenterology

This table cannot be relied upon in the absence of: PA Medical Directive #8 - Gastroenterology Title and Number f Directive: Order Table PA-8: Gastrenterlgy This table cannt be relied upn in the absence f: PA Medical Directive #8 - Gastrenterlgy 1. OVERALL CONDITIONS - The PA may evaluate and prvide

More information

Policy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning

Policy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening

More information

APPENDIX A. Comparability Ratios for the Major Causes of Death in North Carolina Vital Statistics, Volume 2

APPENDIX A. Comparability Ratios for the Major Causes of Death in North Carolina Vital Statistics, Volume 2 APPENDIX A Comparability Ratios for the Major Causes of Death in North Carolina Vital Statistics, Volume 2 The comparability ratio is an adjustment factor that is applied to the number of deaths coded

More information

Field Epidemiology Training Program

Field Epidemiology Training Program Field Epidemilgy Training Prgram Cancer Curriculum: Principles f Cancer Registries Case Study: Hspital-Based Cancer Registries FACILITATOR GUIDE FETP Cancer Curriculum: Principles f Cancer Registries Case

More information

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least

More information

Community Health Worker / Certified Recovery Specialist Training Application

Community Health Worker / Certified Recovery Specialist Training Application APPLICANTS REQUIRED TO COMPLETE APPLICATION WITHOUT ASSISTANCE FROM OTHERS $35 Applicatin Fee is nn-refundable Applying des NOT guarantee admissin int training Date f Applicatin: First Name: Last Name:

More information

8. Preparation of an electronic atlas of amenable mortality (Results of work package 7)

8. Preparation of an electronic atlas of amenable mortality (Results of work package 7) 8. Preparation of an electronic atlas of amenable mortality (Results of work package 7) Authors: Iris Plug, Rasmus Hoffmann, Frank Santegoeds, Johan Mackenbach Affiliation: Erasmus MC, Rotterdam, The Netherlands

More information

Health for Life Chiropractic At Cloverdale Mall Unit # The East Mall Etobicoke, ON, M9B 3Y

Health for Life Chiropractic At Cloverdale Mall Unit # The East Mall Etobicoke, ON, M9B 3Y Health fr Life Chirpractic At Clverdale Mall Unit #143-250 The East Mall Etbicke, ON, M9B 3Y8 416-232-1822 416-232-0060 Child and Adlescent Health Questinnaire Name:_ Birth date: Address:_ Telephne: Medical

More information

CDC Influenza Division Key Points MMWR Updates February 20, 2014

CDC Influenza Division Key Points MMWR Updates February 20, 2014 CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February

More information

Generic Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations

Generic Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment

More information

MANITOBA HEALTH, HEALTHY LIVING & SENIORS WEEKLY WEST NILE VIRUS SURVEILLANCE REPORT (WEEK 27)

MANITOBA HEALTH, HEALTHY LIVING & SENIORS WEEKLY WEST NILE VIRUS SURVEILLANCE REPORT (WEEK 27) MANITOBA HEALTH, HEALTHY LIVING & SENIORS WEEKLY WEST NILE VIRUS SURVEILLANCE REPORT (WEEK 27) The weekly West Nile Virus Surveillance Reprt utlines the mst current surveillance data and is psted weekly

More information

2018 CMS Web Interface

2018 CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS

More information

PART III: CONSUMER INFORMATION

PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr ZERIT Stavudine This leaflet is Part III f a three-part Prduct Mngaph published when ZERIT was apprved fr sale in Canada and is designed specifically

More information

Guideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations

Guideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT INJECTIONS OR BLOCKS CPT Cdes: Cervical Thracic Regin: 64490 (+ 64491, +64492), 0213T (+0214T, +0215T) Lumbar Sacral Regin:

More information

IC REPORTABLE COMMUNICABLE DISEASES IN BC Rev. Jan 2017

IC REPORTABLE COMMUNICABLE DISEASES IN BC Rev. Jan 2017 REPORTABLE COMMUNICABLE DISEASES IN BC Rev. Jan 2017 STANDARDS All physicians must urgently reprt certain cmmunicable diseases t Public Health by telephne n the day f identificatin (see list belw). Labratry

More information

Drug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)

Drug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD) Drug Class Review: Lng-acting muscarinic antagnists (LAMAs) fr treatment f chrnic bstructive pulmnary disease (COPD) Cmprehensive Research Plan: Pharmacepidemilgy Unit April 10 th, 2014 ODPRN Drug Class

More information

Randolph-Macon College Student Health Center P.O. Box 5005 Ashland, VA Phone:

Randolph-Macon College Student Health Center P.O. Box 5005 Ashland, VA Phone: Randlph-Macn Cllege Student Health Center P.O. Bx 5005 Ashland, VA 23005 Phne: 804.752.3041 Email: studenthealth@rmc.edu Checklist fr Students and Parents (This page is fr yu t keep) 1. Health Histry Recrds-

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

Package leaflet: Information for the user. GASTROGRAFIN GASTROENTERAL SOLUTION Sodium amidotrizoate and meglumine amidotrizoate

Package leaflet: Information for the user. GASTROGRAFIN GASTROENTERAL SOLUTION Sodium amidotrizoate and meglumine amidotrizoate Due t regulatry changes, the cntent f the fllwing Patient Infrmatin Leaflet may vary frm the ne fund in yur medicine pack. Please cmpare the 'Leaflet prepared/revised date' twards the end f the leaflet

More information

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018 Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered

More information

Folotyn (pralatrexate)

Folotyn (pralatrexate) Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins

More information

Patient Name: Address City State Zip Code. H. Phone W. Phone Cell Phone. Occupation Employer

Patient Name: Address City State Zip Code. H. Phone W. Phone Cell Phone. Occupation Employer Milham Family Chirpractic Address City State Zip Cde H. Phne W. Phne Cell Phne Email Address: Sex M F Marital Status M S D W Date f Birth Age Occupatin Emplyer Referred by: Have yu ever received Chirpractic

More information

Assessment, History and Physical. Renal Ultrasound

Assessment, History and Physical. Renal Ultrasound UROLITHIASIS ALGORITHM Assessment, Histry and Physical Orders Labs- UA, cnsider RFP, CBC, Urine Culture, and UPT Pain meds (see therapeutics chart) IV fluids Imaging Renal Ultrasund Inclusin Criteria:

More information

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals

Erythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals (Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.80 *NON-DIALYSIS* Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit

More information

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.5 Cmpleted: June 14, 2018 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins

More information

Printed copies of this document may not be up to date, obtain the most recent version from Author Position

Printed copies of this document may not be up to date, obtain the most recent version from   Author Position Printed cpies f this dcument may nt be up t date, btain the mst recent versin frm www.cats.nhs.uk Children s Acute Transprt Service Clinical Guidelines Diabetic Ketacidsis Dcument Cntrl Infrmatin Authr

More information

ASCR REPORTABLE LIST (2016)

ASCR REPORTABLE LIST (2016) ASCR REPORTABLE LIST (2016) Casefinding Cdes fr ICD-O-3 Reprtable Diseases The fllwing list is intended t assist in identifying reprtable neplasms fund thrugh casefinding surces that use ICD-9-CM* cdes

More information

The research question: What was discovered in the 1940s that could treat syphilis?

The research question: What was discovered in the 1940s that could treat syphilis? Psychlgy B30 Human Sexuality Sexually Transmitted Infectins Tuskegee Syphilis Experiment Ppulatin: The research questin: What was discvered in the 1940s that culd treat syphilis? Hw many men died f syphilis

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF 0055): Diabetes: Eye Exam Measure Steward: NCQA Web Interface

More information

Name: Date: Period: Notes: The Blood and Lymphatic System

Name: Date: Period: Notes: The Blood and Lymphatic System Name: Date: Perid: Cmpsitin f Bld and their Functins Red Bld Cells (aka ) Structure Ntes: The Bld and Lymphatic System D nt have a like ther cells d Cntain a specialized prtein called Hemglbin cntains

More information

Please list any other health concerns (physical, emotional or mental) in order of importance:

Please list any other health concerns (physical, emotional or mental) in order of importance: 1281 Shppers Rw NATUROPATHIC ADULT INTAKE Naturpathic medical care requires a healthy relatinship between prvider and patient. Yur respnses t the fllwing questins will significantly cntribute t yur dctr's

More information

Bedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review:

Bedfordshire and Hertfordshire DRAFT Priorities forum statement Number: Subject: Prostatism Date of decision: January 2010 Date of review: Bedfrdshire and Hertfrdshire DRAFT Pririties frum statement Number: Subject: Prstatism Date f decisin: January 2010 Date f review: Referral criteria Mst men with lwer urinary tract symptms due t benign

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Fllw-Up Measure Steward: CMS Web Interface V1.0 Page 1 f 22 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE

More information